
Opinion|Videos|March 12, 2025
Clinical Perspectives for Treatment of R/M NPC
Author(s)Nagashree Seetharamu, MD, MBBS
A panelist discusses how community practitioners should monitor for immune-related adverse events when using toripalimab for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC), establish clear patient communication about toxicities, coordinate multidisciplinary care, consider EBV monitoring, and ensure appropriate patient selection to optimize outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What clinical pearls do you have for community practitioners?
- What are some best practices when incorporating immunotherapies such as toripalimab into R/M NPC treatment approaches?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Lung Cancer News Roundup: June 2026
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































